0000899243-20-000907.txt : 20200109 0000899243-20-000907.hdr.sgml : 20200109 20200109192019 ACCESSION NUMBER: 0000899243-20-000907 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200109 FILED AS OF DATE: 20200109 DATE AS OF CHANGE: 20200109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hemrajani Rekha CENTRAL INDEX KEY: 0001771213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 20519201 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aravive, Inc. CENTRAL INDEX KEY: 0001513818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264106690 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: 936-355-1910 MAIL ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Versartis, Inc. DATE OF NAME CHANGE: 20110223 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-09 0 0001513818 Aravive, Inc. ARAV 0001771213 Hemrajani Rekha C/O ARAVIVE, INC., RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098 1 1 0 0 President and CEO Common Stock 2020-01-09 4 A 0 57000 0.00 A 57000 D Stock Options 13.77 2020-01-09 4 A 0 143000 0.00 A 2021-01-09 2030-01-08 Common stock 143000 143000 D Represents the grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock ("Common Stock") of Aravive, Inc. (the "Company"). The RSUs vest as follows: 25% of the shares vest on each of January 9, 2021, January 9, 2022 January 9, 2023 and January 9, 2024, subject to the reporting person's continued service to the Company. The stock option to purchase 143,000 shares of Common Stock vests as follows: 25% of the shares vest on the one year anniversary of the date of grant and the remaining 75% of the shares vest in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Company. /s/ Abel Svitavsky, Attorney-in-fact 2020-01-09